Volume 27, Number 3—March 2021
Research
Extrapulmonary Nontuberculous Mycobacteria Infections in Hospitalized Patients, United States, 2009–2014
, Jennifer Adjemian1, Rebekah A. Blakney, Yi Ling Lai, Sameer S. Kadri, and D. Rebecca Prevots
Table 4
Demographic and clinical characteristics of extrapulmonary nontuberculous mycobacteria cases among hospitalized patients from 82 hospitals, United States, 2009–2014*
| Characteristics | Extrapulmonary NTM, no. (%), n = 831 | Disseminated, no. (%), n = 246 | SST, no. (%), n = 298 | Other, no. (%), n = 264 | Both, no. (%), n = 23 |
|---|---|---|---|---|---|
| Patient characteristic |
|||||
| Sex | |||||
| F | 409 (49) | 98 (40) | 164 (55) | 133 (50) | 14 (61) |
| M |
422 (51) |
148 (60) |
134 (45) |
131 (50) |
9 (39) |
| Race/ethnicity | |||||
| White | 478 (58) | 93 (38) | 228 (77) | 145 (55) | 12 (52) |
| Black | 269 (32) | 138 (56) | 38 (13) | 83 (31) | 10 (43) |
| Other |
84 (10) |
15 (6) |
32 (11) |
36 (14) |
1 (4) |
| Age group, y | |||||
| <18 | 91 (11) | 13 (5) | 43 (14) | 35 (13) | 0 |
| >18–40 | 244 (29) | 121 (49) | 47 (16) | 70 (27) | 6 (26) |
| >40–60 | 266 (32) | 86 (35) | 93 (31) | 78 (30) | 9 (39) |
| >60 |
230 (28) |
26 (11) |
115 (39) |
81 (31) |
8 (35) |
| Ever had | |||||
| Fungal Infection | 92 (11) | 53 (22) | 13 (4) | 22 (8) | 4 (17) |
| HIV infection | 104 (13) | 63 (26) | 9 (3) | 26 (10) | 6 (26) |
| Invasive cardiac procedure | 18 (2) | 4 (2) | 6 (2) | 7 (3) | 1 (4) |
| Cancer | 31 (4) | 11 (4) | 9 (3) | 11 (4) | 0 |
| Other immunologic disorder† |
18 (2) |
8 (3) |
3 (1) |
7 (3) |
0 |
| In-hospital death or discharged to hospice |
47 (6) |
29 (12) |
5 (2) |
12 (5) |
1 (4) |
| Hospital characteristic | |||||
| Region | |||||
| South | 375 (45) | 147 (60) | 94 (32) | 125 (47) | 9 (39) |
| Northeast | 202 (24) | 44 (18) | 95 (32) | 56 (21) | 7 (30) |
| Midwest | 200 (24) | 44 (18) | 88 (30) | 64 (24) | 4 (17) |
| West | 54 (6) | 11 (4) | 21 (7) | 19 (7) | 3 (13) |
| Setting | |||||
| Urban | 764 (92) | 231 (94) | 278 (93) | 234 (89) | 21 (91) |
| Rural | 67 (8) | 15 (6) | 20 (7) | 30 (11) | 2 (9) |
| Teaching status‡ | |||||
| Teaching facility | 686 (83) | 210(85) | 247 (83) | 209 (79) | 20 (87) |
| Not teaching facility | 112 (13) | 30 (12) | 35 (12) | 209 (17) | 3 (13) |
*Data from in Cerner Health Facts database (https://sc-ctsi.org/resources/cerner-health-facts). Both, disseminated and SST infection; SST, skin and soft tissue. †Antineoplastic and immunosuppressive drugs causing adverse effects in therapeutic use, autoimmune disease, not elsewhere classified, common variable immunodeficiency, encounter for antineoplastic immunotherapy, immunodeficiency with predominant T-cell defect, unspecified, other and unspecified nonspecific immunological findings, other specified disorders involving the immune mechanism, personal history of immunosuppression therapy, unspecified disorder of immune mechanism, unspecified immunity deficiency. ‡Status unknown for 33 patients.
1Current affiliation: Centers for Disease Control and Prevention, Atlanta, Georgia, USA.